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Analysis and comment
Health services research
Process evaluation in randomised controlled trials of
complex interventions
Ann Oakley, Vicki Strange, Chris Bonell, Elizabeth Allen, Judith Stephenson, RIPPLE Study Team
Most randomised controlled trials focus on outcomes, not on the processes involved in
implementing an intervention. Using an example from school based health promotion, this paper
argues that including a process evaluation would improve the science of many randomised
controlled trials
“Complex interventions” are health service interven-
tions that are not drugs or surgical procedures, but
have many potential “active ingredients.”1 A complex
intervention combines different components in a
whole that is more than the sum of its parts.2
Randomised controlled trials (RCTs) are the most rig-
orous way to evaluate the effectiveness of interventions,
regardless of their complexity. Because of their
multifaceted nature and dependence on social context,
complex interventions pose methodological chal-
lenges, and require adaptations to the standard design
of such trials.3 This paper outlines a framework for
using process evaluation as an integral element of
RCTs. It draws on experience from a cluster
randomised trial of peer led sex education.
Why evaluate processes?
Conventional RCTs evaluate the effects of interven-
tions on prespecified health outcomes. The main ques-
tion is, “Does it work?” Process evaluations within trials
explore the implementation, receipt, and setting of an
intervention and help in the interpretation of the out-
come results. They may aim to examine the views of
participants on the intervention; study how the
intervention is implemented; distinguish between
components of the intervention; investigate contextual
factors that affect an intervention; monitor dose to
assess the reach of the intervention; and study the way
effects vary in subgroups.4 Process evaluation can help
to distinguish between interventions that are inher-
ently faulty (failure of intervention concept or theory)
and those that are badly delivered (implementation
failure).5 Process evaluations are especially necessary in
multisite trials, where the “same” intervention may be
implemented and received in different ways.
Although “process” and “qualitative” are often used
interchangeably, data for process evaluation can be
both quantitative and qualitative. For example, in a
series of systematic reviews of research on health pro-
motion and young people, 33 (62%) of 53 process
evaluations collected only quantitative data, 11 (21%)
collected only qualitative data, and nine (17%)
collected both.6 Process evaluation in RCTs is common
in health promotion and public health, but often data
are not collected systematically and are used mostly for
illustration.5
Process evaluation in the RIPPLE study
The RIPPLE (randomised intervention of pupil peer
led sex education) study is a cluster RCT designed to
investigate whether peer delivered sex education is
more effective than teacher delivered sessions at
decreasing risky sexual behaviour. It involves 27
English secondary schools and follow-up to age 19. In
the schools randomised to the experimental arm,
pupils aged 16-17 years (given a brief training by an
external team) delivered the programme to two
successive year cohorts of 13-14 year olds. Control
schools continued with their usual teacher led sessions.
The trial was informed by a systematic review and pilot
study in four schools.7 8 Its design by a multidisciplinary
research team includes an integral process evaluation
that has four aims: to document the implementation of
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the peer led intervention and sex education in control
schools; to describe and compare processes in the two
forms of sex education; to collect information from
study participants (schools and students) about the
experience of taking part in the trial; and to collect data
on individual school contexts.9
Several methods were used to collect process data
(box 1), including questionnaire surveys, focus groups,
interviews, researcher observations, and structured
field notes. Some methods, such as questionnaire
surveys, were also used to collect outcome data. Other
methods, such as focus groups and interviews with
school staff and peer educators, were specific to
process evaluation.
The outcome results by age 16 showed that the
peer led approach improved some knowledge
outcomes; increased satisfaction with sex education;
and reduced intercourse and increased confidence
about the use of condoms in girls. Girls in the peer led
arm reported lower confidence about refusing
unwanted sexual activity (borderline significance). The
incidence of intercourse before age 16 in boys and of
unprotected first sex, regretted first intercourse (or
other quality measure of sexual experiences or
relationships), confidence about discussing sex or con-
traception, and some knowledge outcomes for both
girls and boys were not affected.10
We analysed process data in two stages. Before ana-
lysing outcome data (box 2), we analysed the data to
answer questions arising from the aims outlined above.
The hypotheses generated were tested in statistical
analyses that integrated process and outcome data to
address three questions:
x What was the relation between trial outcomes and
variation in the extent and quality of the implementa-
tion of the intervention?
x What processes might mediate the observed
relation between intervention and outcomes?
x Did subgroups of students and schools differ in
their responses to the intervention?
We used several strategies to combine the different
types of data. These included on-treatment analyses, in
which results for students who received the peer led
intervention were compared with results from the
standard intention to treat approach (where allocation
to, rather than receipt of, the intervention forms the
basis of the analysis). We then carried out regression
analyses and, where appropriate, tests for interactions,
to examine the relation between key dimensions of sex
education, subgroups of schools and students most
and least likely to benefit from the peer led
programme, and study outcomes (further details are
available elsewhere).11 12 We used regression analyses
because they are best for dealing with many types of
outcome, assessing the impact of mediating factors,
and analysing subgroups.13 14
These strategies provided answers to our three
questions.
x More consistent implementation of the peer led
programme might have had a greater impact on
several knowledge outcomes and reduced the propor-
tion of boys having sex by age 16, but it would not have
changed other behavioural outcomes.
x There were key interactions between the extent to
which sex education is participative and skills based
and who provided it: when sex education was
participative and skills based, the peer led intervention
was more effective, but when these methods were not
used, teacher led education was more effective.
x Peer led sex education was less good at engaging
students most at risk of poor sexual health (risk was
assessed using housing tenure, attitude to school, and
educational aspirations); the peer led approach was
better at increasing knowledge in schools serving
“medium” rather than “low” risk populations (assessed
using the proportion of students receiving free school
meals).
Integrating process and outcome
evaluation
Process evaluation in the RIPPLE trial is an example of
the trend to move beyond the rhetoric of quantitative
versus qualitative methods. By integrating process and
outcome data, we maximised our ability to interpret
results according to empirical evidence. Importantly,
an on-treatment approach to outcomes using process
data made little difference to the results. Using process
data to identify key dimensions of sex education and
examining these in relation to the trial arm revealed
the circumstances in which peer led sex education was
most effective, as did analysis of risk for both individual
schools and students. The conclusion that the peer led
approach is not a straightforward answer to the
problem of school disengagement and social exclusion
is an important policy message.
Other recent trials of complex interventions in
which integral process evaluations helped explain the
outcome findings include a trial of peer education for
homosexual men that had no apparent impact on HIV
risk behaviour; the process evaluation established that
the intervention was largely unacceptable to the peer
educators recruited to deliver it.15 In trials of day care
for preschool children and of supportive health
visiting for new mothers, integral process evaluations
revealed unpredicted economic effects of day care and
Box 1: Methods for data collection in the
RIPPLE trial process evaluation
• Questionnaire surveys of students and peer
educators
• Focus groups with students and peer educators
• Interviews with teachers
• Researcher observation of peer led and teacher led
sex education
Box 2: Methodological issues of integrating
process evaluation within trials
• Process data should be collected from all
intervention and control sites
• Data should be both qualitative and quantitative
• Process data should be analysed before outcome
data to avoid bias in interpretation
• Steps should be taken to minimise the possibility of
bias and error in interpreting the findings from
statistical approaches, such as on-treatment analyses
and regression and subgroup analyses
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the reasons for low uptake of health visiting in a cultur-
ally diverse population.16 17 In a trial of a secondary
prevention programme for cardiovascular disease,
interviews and focus groups showed that because
patients viewed heart attacks as self limited episodes,
they were less willing to adopt long term lifestyle
changes, and that the ability of practice nurses to pro-
vide skilled continuity of care was affected by their lack
of training and low status in the primary health care
team.18 Such trials involve issues of service and organi-
sation and the frameworks of understanding that
inform the behaviour of healthcare users—features of
the interactions between intervention and environ-
ment that characterise complex interventions.19
“Good” randomised controlled trials have been
defined as those having a high quality intervention,
adequate evaluation of the intervention and its
delivery, documentation of external factors that may
influence outcome, and a culturally sensitive interven-
tion.20 Thus, many RCTs would be enhanced by an
integral process evaluation. The additional costs (such
as collecting and analysing qualitative data) would
probably be balanced by greater explanatory power
and understanding of the generalisability of the
intervention.21 Complexity as a quality of interventions
is a matter of degree, not an absolute. The argument
that process evaluation is most useful in cluster trials,
and where the intervention is non-standardised, also
applies to many “pragmatic” clinical RCTs,22 as does
the idea that process evaluation in feasibility studies is
crucial to developing appropriate and effective
interventions.23
A “social” model of RCTs?
The move towards combining process and outcome
evaluation builds on other, related methodological
developments. For example, more attention is being
paid to the need for pilot and consultation work in the
development phase of RCTs,23 the importance of a
more theory based approach to evaluation,24 and the
modification of intervention effects by context in com-
munity intervention trials.25 Statistical methods to inte-
grate process and outcome data, such as those
developed in the RIPPLE study, are a move forward.
Some of the methods we suggest—such as allowing
hypotheses about the effectiveness of interventions to
be derived from process data collected during a trial,
and drawing conclusions (with reservations) from
on-treatment and subgroup analyses—go against the
conventions of clinical RCTs. Perhaps the effort
devoted to developing “how to do it” guidelines for
clinical trials could be matched by a similar effort in the
field of complex interventions.
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Drugs
Lessons for clinical trials from natalizumab in multiple
sclerosis
Abhijit Chaudhuri
The approval of natalizumab and its recall after three months raises questions about the fast tracking
of new drugs by the Food and Drug Administration for commercial licensing
On 28 February 2005 Biogen Idec and Elan voluntar-
ily suspended marketing natalizumab (Tysabri or Ante-
gren) for clinical use because two patients with
multiple sclerosis developed progressive multifocal
leucoencephalopathy (PML) while being treated. Clini-
cians were advised to suspend all ongoing trials, and
commercial distribution of the drug was halted. Three
months earlier the US Food and Drug Administration
gave natalizumab accelerated approval to treat
relapsing multiple sclerosis. Approval was given on the
basis of short term (one year) data from two multi-
centre, randomised double blind placebo controlled
phase 3 trials. Neither trial was published in a peer
reviewed journal and the FDA granted approval before
final trial and cumulative safety data were available.
PML has been confirmed in three patients taking
natalizumab.1–3
The unpublished multiple sclerosis trials
Natalizumab is a humanised monoclonal antibody to
4 integrin, which plays a key role in the adhesion and
migration of immunocompetent T cells through its
interaction with endothelial selective adhesion mol-
ecule.4 Approximately 3000 patients, mostly with mul-
tiple sclerosis and Crohn’s disease, were treated with
natalizumab in clinical trials, and nearly 5000 patients
have been treated in the United States since it became
commercially available in 2004. In the United
Kingdom, natalizumab was due for appraisal by the
National Institute for Health and Clinical Excellence in
2006 for use in multiple sclerosis.
In the two studies that formed the basis of its
approval by the FDA, natalizumab was given intrave-
nously every four weeks to patients with multiple scle-
rosis who had experienced at least one clinical relapse
during the preceding year. The primary end point of
each study was the annualised relapse rate at one year.
In the first trial (the AFFIRM trial) patients were
randomised 2:1 to receive natalizumab (n = 627) or
placebo (n = 315). In the second study (the SENTINEL
trial) patients had experienced at least one relapse,
despite treatment with interferon beta-1a (Avonex;
Biogen Idec). Patients were randomised to receive
natalizumab (n = 589) or placebo (n = 582) in addition
to intramuscular injections of interferon beta-1a. In the
first study, patients receiving natalizumab had a relapse
rate of 0.25 relapses per patient year, compared with
0.74 in the placebo group (66% relative reduction of
relapses). In the second study, patients taking natalizu-
mab had 0.36 relapses per patient year compared with
0.78 in the placebo group (54% relative reduction of
relapses). The FDA concluded that natalizumab was
superior to all available treatments for relapsing multi-
ple sclerosis (three types of interferon beta and
glatiramer).5
Safety data were available to the FDA for
1617 patients treated for multiple sclerosis in both
controlled and uncontrolled studies.5 The median
exposure time to the drug was 20 months and the most
frequent serious adverse events were infection,
hypersensitivity reactions, and depression.5
T cell attacking a cluster of foreign red blood cells: natalizumab
prevents the migration of immunocompetent T cells across biological
barriers and suppresses T cell mediated immune responses
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